

Variant: *NM\_000552.5(VWF):c.3926T>A (p.Ile1309Asn)*

Version: 1.0

[CA383506185](#)

[1684483 \(ClinVar\)](#)

**Gene:** VWF ([HGNC:7450](#))

**Condition:** von Willebrand disease type 2B ([MONDO:0015629](#))

**Inheritance Mode:** Autosomal dominant inheritance

**UID:** 3f3d0c7b-a702-4ea7-a03a-15e8fc2e2fb8

**Approved on:** 2025-05-06

**Published on:** 2025-05-09

### HGVS expressions

**NM\_000552.5:c.3926T>A**

NM\_000552.5(VWF):c.3926T>A (p.Ile1309Asn)

NC\_000012.12:g.6019492A>T

CM000674.2:g.6019492A>T

NC\_000012.11:g.6128658A>T

CM000674.1:g.6128658A>T

NC\_000012.10:g.5998919A>T

NG\_009072.1:g.110179T>A

NG\_009072.2:g.110179T>A

ENST00000261405.10:c.3926T>A

ENST00000261405.9:c.3926T>A

ENST00000538635.5:n.421-25558T>A

NM\_000552.3:c.3926T>A

NM\_000552.4:c.3926T>A

**Likely Pathogenic**

Met criteria codes **4**

PP3 PM5 PM2\_Supporting

PP4\_Moderate

Evidence Links **0**

Expert Panel

[von Willebrand Disease VCEP](#)

Criteria Specification Information

[Criteria Specification:](#) *ClinGen von Willebrand Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for VWF Version 1.0.0*

[Criteria Specification Approval History](#)

[Criteria Specifications for this VCEP](#)









Evidence submitted by expert panel

**von Willebrand Disease VCEP**

The NM\_000552.5(VWF):c.3926T>A (p.Ile1309Asn) missense variant is absent from gnomAD v4.1 (PM2\_Supporting). The computational predictor REVEL gives a score of 0.886, which is above the ClinGen VWD VCEP threshold of >0.644 and predicts a damaging effect on VWF function (PP3). Another type 2B missense change (p.I1309V) has been reported at this amino acid residue and has been classified Pathogenic for type 2B VWD by the VWD VCEP (PM5). At least one patient with this variant displayed excessive mucocutaneous bleeding

as well as a laboratory phenotypes of thrombocytopenia and an assay showing gain of function (flow cytometry showed markedly increased baseline activity), which together are highly specific for VWD type 2B. (PP4\_moderate, SCV002515788.1). The patient was also reported to a VWF antigen/activity ratio (0.2) consistent with type 2B. In summary, this variant has been classified as likely pathogenic for type 2B Von Willebrand Disease based on the ACMG/AMP criteria applied as specified by the von Willebrand Disease Variant Curation Expert Panel. PM2\_supporting, PP3, PM5, PP4\_moderate.

#### Met criteria codes

<b>PP3</b>	 	The computational predictor REVEL gives a score of 0.886, which is above the ClinGen VWD VCEP threshold of >0.644 and predicts a damaging effect on VWF function (PP3).
<b>PM5</b>	 	Another type 2B missense change (p.I1309V) has been reported at this amino acid residue and has been classified Pathogenic for type 2B VWD by the VWD VCEP.
<b>PM2_Supporting</b>	 	This variant is absent from gnomAD v4.1 (PM2_Supporting).
<b>PP4_Moderate</b>	 	At least one patient with this variant displayed excessive mucocutaneous bleeding as well as a laboratory phenotypes of thrombocytopenia and an assay showing gain of function (flow cytometry showed markedly increased baseline activity), which together are highly specific for VWD type 2B. (PP4_moderate, SCV002515788.1). The patient was also reported to a VWF activity/antigen ratio (0.2) consistent with type 2B.

#### Curation History

Showing 1 to 1 of 1 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.